List view / Grid view
In vitro neutralisation assays show REGEN-COV and AZD7442 are effective against the new SARS-CoV-2 variants, while other antibody therapies, including Eli Lilly’s bamlanivimab, were not.
The European Commission approval makes KEYTRUDA® (pembrolizumab) the first anti-PD-1 therapy approved for metastatic microsatellite instability-high (MSI-H) colorectal cancer patients in Europe.
According to a new study, vaccines delivered via skin scarification were better at inducing T cell activity in pre-clinical animal models.
The EMA has accepted Global Blood Therapeutics' marketing authorisation application for Oxbryta (voxelotor) to treat haemolytic anaemia in sickle cell disease.
Data from a Phase III trial shows high-risk patients treated with bamlanivimab and etesevimab were 70 percent less likely to be hospitalised due to COVID-19.
Interim data from the Phase III trial evaluating REGEN-COV™ as a passive vaccine to prevent COVID-19 finds it reduces overall infection rate, viral load and length of infection.
Results from in vitro neutralisation studies have shown that Moderna's COVID-19 vaccine is effective against emerging strains of SARS-CoV-2.
Imvax's Phase Ib clinical trial of IGV-001 for patients with newly diagnosed glioblastoma has shown positive results.
In a Phase IIb trial, hospitalised COVID-19 patients treated with desidustat did not develop acute respiratory distress syndrome (ARDS).
Through COVAX, doses of the Pfizer-BioNTech vaccine will be provided at a not-for-profit price for 92 low- and lower-middle-income countries.
AbbVie's RINVOQ (upadacitinib) has been approved in the EU to treat adult patients with active psoriatic arthritis (PsA).
Following Phase I results, Merck will discontinue its development of V590 and V591, two COVID-19 vaccine candidates.
![Vial labelled heparin. [Credit: SamaraHeisz5 / Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Heparin-300x278.jpg)
![Vial labelled heparin. [Credit: SamaraHeisz5 / Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Heparin-scaled.jpg)
Interim data from 1,000 hospitalised patients with moderate COVID-19 symptoms shows that full doses of heparin can improve patient outcomes and could reduce ICU burden.
Treatment with XPro1595 for three months caused significant changes in neurodegeneration, synaptic function and neuroinflammation.
NICE has recommended that the CAR T-cell therapy Tecartus be given to patients with relapsed or refractory mantle cell lymphoma.
